Sumitomo Pharma Co Ltd 2023 IR
The report outlines Sumitomo Pharma Group's performance for fiscal 2022 and its strategic transition under the new Mid-term Business Plan 2027. Facing the loss of exclusivity for its blockbuster drug LATUDA in the U.S., the company is focusing on maximizing the value of its three key products: ORGOVYX, MYFEMBREE, and GEMTESA. Additionally, the company is accelerating its research and development in priority areas like psychiatry & neurology, oncology, and regenerative medicine/cell therapy. Sumitomo Pharma is also advancing its digital transformation and has committed to the Science Based Targets initiative to reduce greenhouse gas emissions.
Company: Sumitomo Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 114
Sumitomo Pharma Co Ltd
Integrated Report
The report outlines Sumitomo Pharma Group's performance for fiscal 2022 and its strategic transition under the new Mid-term Business Plan 2027. Facing the loss of exclusivity for its blockbuster drug LATUDA in the U.S., the company is focusing on maximizing the value of its three key products: ORGOVYX, MYFEMBREE, and GEMTESA. Additionally, the company is accelerating its research and development in priority areas like psychiatry & neurology, oncology, and regenerative medicine/cell therapy. Sumitomo Pharma is also advancing its digital transformation and has committed to the Science Based Targets initiative to reduce greenhouse gas emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Published
Oct 1, 2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Women in Management
Net Zero Target
Employees